Imaxio announces the first human clinical trial using its...

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study.

http://www.medilexicon.com/medicalnews.php?newsid=265633

Imaxio Announces the First Human Clinical Trial Using Its...

Lyon, France, September 3, 2013 - Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study.

http://www.biospace.com/news_story.aspx?StoryID=307416&full=1